Treatment of lymphangioleiomyomatosis

Daniel M. Goodenberger, Sandeep Dhand, Arn H. Eliasson, Yancy Y. Phillips, Michael F. Tenholder, Thomas Murphy Goodwin, Johannes Zahner, Mathias M. Borst, Heinrich Worth, Thomas A. Raffin, James R. Taylor, Jay Ryu, Thomas V. Colby

Research output: Contribution to journalLetter

3 Scopus citations

Abstract

To the Editor: The article on lymphangioleiomyomatosis (LAM) by Taylor et al. (Nov. 1 issue)* was a very useful addition to the limited literature on the disease. I take issue with one of their recommendations, however. Despite their own finding that oophorectomy is not associated with an observable clinical benefit, they continue to recommend it as second-line therapy because studies to date cannot exclude a possible benefit. Perhaps the following hypothetical encounter with a patient will illustrate my point. “Mr. Jones, your open-lung biopsy showed a form of interstitial lung disease about which we know very little. The natural history.

Original languageEnglish (US)
Pages (from-to)63-64
Number of pages2
JournalNew England Journal of Medicine
Volume325
Issue number1
DOIs
StatePublished - Jul 4 1991

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Treatment of lymphangioleiomyomatosis'. Together they form a unique fingerprint.

  • Cite this

    Goodenberger, D. M., Dhand, S., Eliasson, A. H., Phillips, Y. Y., Tenholder, M. F., Goodwin, T. M., Zahner, J., Borst, M. M., Worth, H., Raffin, T. A., Taylor, J. R., Ryu, J., & Colby, T. V. (1991). Treatment of lymphangioleiomyomatosis. New England Journal of Medicine, 325(1), 63-64. https://doi.org/10.1056/NEJM199107043250115